

QIBA PET-Amyloid Biomarker Committee (BC) Call

10 August 2018 at 9:00 AM CT

Call Summary

Some additional notes added by Ms. Matthews

In attendance:			RSNA
Dawn Matthews, MS, MBA (Co-Chair)	Rachid Fahmi, MSc, PhD	Jean-Luc Vanderheyden, PhD	Joe Koudelik
Satoshi Minoshima, MD, PhD (Co-Chair)	Nancy Obuchowski, PhD	Richard Wahl, MD, FACR	Julie Lisiecki
Anne Smith, PhD (Co-Chair)	Eric Perlman, MD	Xiaoyou Ying, PhD	
Tammie Benzinger, MD, PhD			

Moderator: Ms. Matthews

Technical Feasibility Process

- The Amyloid Profile was approved for publishing as Consensus (Stage #2) by the Amyloid BC and NM CC
 - Public comment has been addressed
- The next step is to create a site feasibility questionnaire for use in clinical applications or clinical trials
 - A questionnaire will be created based on the normative Profile text to gain site feedback in order to create a practical site checklist
 - Real world site input is needed to make the checklist efficient as well as to inform the Profile regarding what may need to be revised to improve it
- The questionnaire will ask respondents to select from the following:
 - Currently in practice; Feasible; Feasible, but not going to implement
 - Based upon discussion during the call, the “Feasible” category may be more representative than the “Currently in practice”, because sites may implement certain practices according to the relevant protocol, which may vary depending upon the intended use.

Potential list of volunteer Technically Confirmed Sites:

- UT Southwestern (Dr. Subramaniam)
- Wash U (Dr. Wahl)
- 2-3 high-power academic sites needed to start, with the hope to expand to an additional 7 centers (for a total of 10) that may represent the broader community
- Dr. Minoshima suggested that some sites from those that provided comments on the Profile could be approached for this effort (these sites have already demonstrated a willingness to review the content that would be included in the questionnaire)

Regarding the spreadsheet:

- Suggestion that the volunteer sites fill in columns F & G, similarly to what was done for the FDG Profile
 - Group discussion that filling in columns F & G is not necessary – column E would be clear enough; it is desirable to reduce any unnecessary or redundant time spent on re-phrasing requirements
- It was suggested that web/telephone interviews of sites might allow for faster and more efficient feedback
- Europe may be doing more clinical Amyloid scanning due to different reimbursement criteria
- Dr. Smith will evaluate the spreadsheet on behalf of Siemens PET/CT products re: vendor conformance
- Ms. Matthews will review the spreadsheet for any intended changes per public comment that may have not been included in all relevant boxes of the edited version (one example is the inclusion of “qualified personnel” in administration of a radiotracer)
- Version control is important to make sure that the latest version is being used

Nuclear Medicine WebEx Schedule:

09/07 FDG-PET BC

09/11 TC ^{99m} BC @ 2pm CT

09/14 PET Amyloid BC

09/21 I-123 BC - *TBD*

09/28 NM Coordinating Committee